Doctors Hospital Health System Limited Interim report Quarter ended April 30, 2023

Chairman's Report Doctors Hospital Health System Limited

Dear Shareholder.

On behalf of the Board of Directors of Doctors Hospital Health System, I report on your company's financial results for the three months ended April 30, 2023.

Consolidated net profit for the three months was \$4,249,992 compared to a profit of \$1,962,01 for the comparable period in the prior fiscal year. Doctors Hospital (Bahamas) Limited's profit was \$2,433,624 compared with \$1,788,860, and Bahamas Medical Center's profit was \$1,816,368 compared with \$173,152 for the comparable period in the prior fiscal year.

Consolidated net patient revenue increased \$6,663,276 or 28.42% over the 1st quarter last year. Total inpatient days also increased (53.32%) compared to the same period last year, with 4,270 patient days for the 1st quarter this year compared to 2,785 in the 1st quarter last year. The impact of the agreement with the Government of The Bahamas to treat patients at Doctors Hospital West increased patient days to 1,455 for the 1st quarter this year compared to 67 patient days in the 1st quarter last year. Net patient service revenue for Doctors Hospital West was \$3,080,593 in the 1st quarter this year compared to \$843,312 in the 1st quarter last year.

Consolidated expenses increased \$4,570,191 or 112.04%, over the comparable period last year, which was driven predominantly by variable costs incurred in delivering increased services during the period, such as outside services, salaries & benefits and bad debt expense. Outside services increased as a result of IT consultants being utilized by the Group during the period associated with an upgrade to the Group's electronic health record system. Salaries & benefits grew as a result of additions to the employee headcount relating to the expansions to our operations in FY 2023. Bad debt expense increased due to an increase in loss rates during the expected credit loss assessment for the accounts receivable portfolio.

The Board joins me in thanking our valued shareholders, for your continued support and loyalty to the Hospital. We extend an invitation for you to join us at our Company's hybrid Annual General Meeting on October 5, 2023 virtually and in person at Doctors Hospital's Conference Center on Dowdeswell Street.

Felix Stubbs Chairman September 4, 2023

Consolidated Statement of Financial Position

April 30, 2023 with comparative figures at January 31, 2023 (Expressed in thousands of Bahamian dollars)

	April 30, 2023		January 31, 2023	
Assets				
Current assets:				
Cash and cash equivalents	\$	8,184	18,172	
Accounts receivable—patients, net (note 2)	~	13,032	13,653	
Accounts receivable—third party payors, net (note 2)		32,267	23,793	
Inventories		7,389	5,405	
Prepaid expenses & other assets		8,816	6,732	
		69,688	67,755	
Non-current assets:		,	,	
Investments –Fixed Income		6,946	6,878	
Investments		30	30	
Goodwill, net		431	431	
Other intangible assets		259	266	
Property, plant and equipment		51,641	43,353	
Right of use assets		3,160	3,469	
ragin of all all all all all all all all all al		62,467	54,427	
Total assets	\$	132,155	122,182	
Total assets	Ψ	132,133	122,102	
Liabilities and Shareholders' Equity Current liabilities:				
Accounts payable and other liabilities	\$	28,482	22,444	
Lease liabilities, current portion	Ψ	1,060	1,173	
Long-term debt, current portion		251	249	
zeng wim ees, emem penen		29,793	23,866	
			20,000	
Long-term liabilities:				
Lease liabilities		2,321	2,503	
Long-term debt		2,933	2,955	
		5,254	5,458	
Total liabilities		35,047	29,324	
Shareholders' equity: Share capital: Authorized 12,500,000 common shares at par value of B\$0.04 each (January 31, 2023 – 12,500,000 shares)				
Issued and fully paid 11,971,634 shares		470	470	
(January 31, 2023 – 11,971,634 shares)		479 25 779	479	
Contributed surplus		25,778 70,951	25,778	
Retained earnings		70,851	66,601	
The state of the s	Φ.	97,108	92,858	
Total liabilities and shareholders' equity	\$	132,155	122,182	

Consolidated Statement of Comprehensive Income

Three months ended April 30, 2023 with comparative figures for the three months ended April 30, 2022 (Expressed in thousands of Bahamian dollars)

		ril 30, 2023	April 30, 2022	
Revenues				
Patient service revenue, net	\$	30,108	23,445	
Other		1,469	1,274	
Total revenues		31,577	24,719	
Expenses				
Salaries and benefits		11,372	9,744	
Medical supplies		1,064	3,322	
Medical services		3,179	2,469	
Bad debt expense, net of recoveries		2,539	575	
Depreciation and amortization		1,120	996	
Other operating		1,380	1,605	
Utilities		695	430	
Government taxes and fees		860	836	
Outside services		3,686	1,447	
Insurance		515	375	
Repairs and maintenance		412	543	
Rent		101	47	
Dietary expenses		216	147	
Legal expenses		103	139	
Interest expense		85	82	
Total expenses		27,327	22,757	
Net income & total comprehensive				
income for the period	\$	4,250	1,962	
Earnings per common share (expressed in Bahamian dollars):				
Basic and fully diluted	\$	0.36	0.16	

Consolidated Statement of Changes in Equity

Three months ended April 30, 2023 (Expressed in thousands of Bahamian dollars)

	Number of shares	Share capital	Contributed surplus	Retained earnings	Total
Balance at January 31, 2023	11,971,634	\$ 479	\$ 25,778	\$ 66,601	\$ 92,858
Net income for the period	_	_	_	4,250	4,250
Dividends paid	_	_	_	-	-
Balance at April 30, 2023	11,971,634	\$ 479	\$ 25,778	\$ 70,851	\$ 97,108

Consolidated Statement of Cash Flows

Three months ended April 30, 2023 with comparative figures for the three months ended April 30, 2022 (Expressed in thousands of Bahamian dollars)

	April 30, 2023		April 30, 2022	
CASH FLOWS FROM OPERATING ACTIVITIES:				
Net income	\$	4,250	1,962	
Adjustments to reconcile net income to net cash				
provided by operating activities:				
Depreciation and amortization		1,120	996	
Provision for doubtful accounts		2,539	575	
Interest expense		85	82	
Operating income before working capital changes		7,994	3,615	
Increase in accounts receivable		(9,834)	(225)	
(Increase)/decrease in inventories		(1,984)	3,245	
Increase in prepaid expenses and other assets		(2,084)	(6,614)	
Increase/(decrease) in accounts payable and other liabilities		5,480	673	
Net cash used in operating activities		(428)	(1,746)	
CASH FLOWS FROM INVESTING ACTIVITIES:				
Purchase of property, plant and equipment		(9,137)	(3,084)	
(Purchase)/maturity of investments		(68)	13,163	
Net cash (used in)/provided by investing activities		(9,205)	10,079	
CASH FLOWS FROM FINANCING ACTIVITIES:				
Repayment of long-term debt		(19)	(58)	
Payment of lease liabilities		(295)	(861)	
Interest paid		(41)	(55)	
Net cash used in financing activities		(355)	(974)	
(Decrease)/increase in cash and cash equivalents		(9,988)	7,359	
Cash and cash equivalents at beginning of period		18,172	6,760	
Cash and cash equivalents at end of period	\$	8,184	14,119	

Cash and cash equivalents comprise cash at bank and in hand, and short-term deposits with an original maturity of three months or less.

Notes to Interim Consolidated Financial Statements

Three months ended April 30, 2023

1. Significant accounting policies

These interim financial statements have been prepared in accordance with International Accounting Standard No. 34, Interim Financial Reporting; using the same accounting policies applied in the January 31, 2023 audited consolidated financial statements.

2. Accounts receivable

Accounts receivable are stated net of provisions for doubtful accounts of \$6.2 million.